These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 26409125)
1. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations. Brittain ST; Wheless JW Epilepsy Behav; 2015 Nov; 52(Pt A):31-6. PubMed ID: 26409125 [TBL] [Abstract][Full Text] [Related]
2. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation. Bialer M; Shekh-Ahmad T; Braun TL; Halvorsen MB Epilepsia; 2013 Aug; 54(8):1444-52. PubMed ID: 23692553 [TBL] [Abstract][Full Text] [Related]
3. The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. Gidal BE; Clark AM; Anders B; Gilliam F Epilepsy Res; 2017 Jan; 129():26-32. PubMed ID: 27883934 [TBL] [Abstract][Full Text] [Related]
4. Assessing impact of real-world dosing irregularities with lamotrigine extended-release and immediate-release formulations by pharmacokinetic simulation. Chen C; Wright J; Gidal B; Messenheimer J Ther Drug Monit; 2013 Apr; 35(2):188-93. PubMed ID: 23503444 [TBL] [Abstract][Full Text] [Related]
6. Lacosamide extended-release capsules are bioequivalent to lacosamide immediate-release tablets: Pharmacokinetic observations and simulations. Wheless J; Gidal B; Gong L; Lyu S; Zheng X; Li R; Chang W; Tan M Epilepsy Res; 2024 May; 202():107350. PubMed ID: 38513537 [TBL] [Abstract][Full Text] [Related]
7. Real-world assessment of treatment with extended-release topiramate (Trokendi XR O'Neal W; Hur EE; Liranso T; Patel B J Comp Eff Res; 2018 Nov; 7(11):1095-1105. PubMed ID: 30136603 [TBL] [Abstract][Full Text] [Related]
8. Use of computer simulations to test the concept of dose forgiveness in the era of extended-release (XR) drugs. Pellock JM; Brittain ST Epilepsy Behav; 2016 Feb; 55():21-3. PubMed ID: 26724400 [TBL] [Abstract][Full Text] [Related]
9. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). Tompson DJ; Ali I; Oliver-Willwong R; Job S; Zhu L; Lemme F; Hammer AE; Vuong A; Messenheimer JA Epilepsia; 2008 Mar; 49(3):410-7. PubMed ID: 17825077 [TBL] [Abstract][Full Text] [Related]
10. USL255 extended-release topiramate: dose-proportional pharmacokinetics and tolerability in healthy volunteers. Clark AM; Halvorsen MB; Braun TL; Johnson KM; Cloyd JC Epilepsia; 2014 Jul; 55(7):1069-76. PubMed ID: 24861853 [TBL] [Abstract][Full Text] [Related]
11. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Doose DR; Brodie MJ; Wilson EA; Chadwick D; Oxbury J; Berry DJ; Schwabe S; Bialer M Epilepsia; 2003 Jul; 44(7):917-22. PubMed ID: 12823574 [TBL] [Abstract][Full Text] [Related]
12. Preparation, Characterization and in vivo Evaluation of Simple Monolithic Ethylcellulose-coated Pellets Containing Topiramate with Biphasic Release Characteristics. Gong W; Wang Y; Shao S; Xie S; Shan L; Yang M; Gao C; Zhong W Curr Drug Deliv; 2016; 13(2):245-54. PubMed ID: 26563941 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection. Yong CL; Gathe JC; Knecht G; Orrell C; Mallolas J; Podzamczer D; Trottier B; Zhang W; Sabo JP; Vinisko R; Drulak M; Quinson AM HIV Clin Trials; 2017; 18(5-6):189-195. PubMed ID: 29210627 [TBL] [Abstract][Full Text] [Related]
14. Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food. Lamba M; Wang R; Fletcher T; Alvey C; Kushner J; Stock TC J Clin Pharmacol; 2016 Nov; 56(11):1362-1371. PubMed ID: 26970526 [TBL] [Abstract][Full Text] [Related]
15. Usefulness of extended-release topiramate in patients with epilepsy: A two-year retention study. Lee H; Kim DW J Clin Pharm Ther; 2021 Oct; 46(5):1412-1417. PubMed ID: 34146432 [TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. Lambrecht LJ; Shekh-Ahmad T; Todd WM; Halvorsen MB; Bialer M Epilepsia; 2011 Oct; 52(10):1877-83. PubMed ID: 21770925 [TBL] [Abstract][Full Text] [Related]
17. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Timmins P; Donahue S; Meeker J; Marathe P Clin Pharmacokinet; 2005; 44(7):721-9. PubMed ID: 15966755 [TBL] [Abstract][Full Text] [Related]
18. Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects. Anderson GD; Saneto RP CNS Drugs; 2015 Aug; 29(8):669-81. PubMed ID: 26369919 [TBL] [Abstract][Full Text] [Related]